Your browser doesn't support javascript.
loading
Bystander T cells in cancer immunology and therapy.
Meier, Stefanie L; Satpathy, Ansuman T; Wells, Daniel K.
Afiliação
  • Meier SL; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Satpathy AT; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Wells DK; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Nat Cancer ; 3(2): 143-155, 2022 02.
Article em En | MEDLINE | ID: mdl-35228747
ABSTRACT
Cancer-specific T cells are required for effective anti-cancer immunity and have a central role in cancer immunotherapy. However, emerging evidence suggests that only a small fraction of tumor-infiltrating T cells are cancer specific, and T cells that recognize cancer-unrelated antigens (so-called 'bystanders') are abundant. Although the role of cancer-specific T cells in anti-cancer immunity has been well established, the implications of bystander T cells in tumors are only beginning to be understood. It is becoming increasingly clear that bystander T cells are not a homogeneous group of cells but, instead, they differ in their specificities, their activation states and effector functions. In this Perspective, we discuss recent studies of bystander T cells in tumors, including experimental and computational approaches that enable their identification and functional analysis and viewpoints on how these insights could be used to develop new therapeutic approaches for cancer immunotherapy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Neoplasias Limite: Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Neoplasias Limite: Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos